HTLV-1 reverse transcriptase homology model provides structural basis for sensitivity to existing...

Area of Science:

• Virology
• Structural Biology
• Drug Discovery

Background:

• Human T-lymphotropic virus type 1 (HTLV-1) causes lifelong infections and severe diseases like adult T cell leukemia/lymphoma.
• No specific antiviral treatments exist for HTLV-1, and the efficacy of human immunodeficiency virus (HIV) drugs is unknown.

Purpose of the Study:

• To investigate the structural basis for potential therapeutic binding to HTLV-1 reverse transcriptase.
• To evaluate the efficacy of existing antiviral drugs against HTLV-1 using computational methods.

Main Methods:

• Homology modeling and machine learning were used to create a structural model of HTLV-1 reverse transcriptase.
• Molecular docking experiments assessed the binding capacity of FDA-approved reverse transcriptase inhibitors.

Main Results:

• Nucleoside/nucleotide reverse transcriptase inhibitors, but not non-nucleoside inhibitors, were predicted to bind HTLV-1 reverse transcriptase.
• Binding affinity was comparable to that observed for HIV-1 reverse transcriptase.

Conclusions:

• In silico structural biology approaches can guide drug design and therapeutic testing for HTLV-1.
• Findings support clinical trials for drugs like tenofovir alafenamide, zidovudine, lamivudine, and azvudine in treating HTLV-1 infections.